Genetic Variations Linked to GLP-1 Weight Loss and Side Effects

New research published in April 2026 suggests that our genes play a meaningful role in how we respond to GLP-1 medications — and which side effects we experience.

According to Reuters, researchers found that people with certain variants of the GLP1R gene lost an extra 1.7 to 3.3 pounds compared to those without the variant, when taking semaglutide. That might not sound like much, but across a year of treatment it compounds into a significant difference.

More strikingly, GIPR gene variants were linked to an 83% higher risk of nausea on tirzepatide. Since tirzepatide acts as both a GLP-1 and GIP agonist, it makes sense that GIP-receptor genetics would affect side-effect profiles for that drug specifically.

This doesn’t mean you need genetic testing before starting a GLP-1. But it does add evidence to the growing idea that weight-loss drugs are not one-size-fits-all. In the future, pharmacogenomic testing could help clinicians choose between semaglutide, tirzepatide, and next-generation drugs based on a patient’s genetic profile.

Frequently Asked Questions

Should I get genetic testing before starting a GLP-1?

Not yet. While the research is promising, pharmacogenomic testing for GLP-1s is not yet standard clinical practice. Your provider will likely use trial and error — starting with one drug and switching if side effects are intolerable or response is poor.

Which drug is better if I have GIPR variants?

The study suggests that people with GIPR variants may tolerate semaglutide better than tirzepatide, since semaglutide does not act on the GIP receptor. However, this is still early research and should not replace clinical judgment.

Will this change how drugs are prescribed?

In the next 3–5 years, yes. As pharmacogenomics becomes cheaper and more accessible, it is likely that clinicians will use genetic data to personalize GLP-1 selection. For now, cost and insurance coverage remain the primary deciding factors.

Source: Reuters